Drug intelligence / Profile preview

ONY382916

Development stage: Unknown
Lead developer: ONY Biotech

Overview

ONY382916 is an investigational drug candidate currently under development by ONY Biotech for the treatment of cardiovascular diseases. As of early 2024, the asset is positioned in the transition between preclinical development and early Phase I clinical trials. ONY Biotech, a company traditionally focused on neonatal respiratory therapies such as its flagship product Infasurf (calfactant), is expanding its therapeutic reach into the cardiovascular space with this candidate. Detailed information regarding the drug's specific molecular target, chemical modality, and mechanism of action has not yet been publicly disclosed by the developer.

Beyond the preview

Go deeper on ONY382916.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ONY382916.

Explore the full profile